Combination studies with statins and immune checkpoint inhibitors, such as programmed cell death protein 1 (PD-1) inhibitors, suggest that statins may modulate the TME to enhance immune responses,55 representing a shift toward targeting cancer cell biology and tumor interactions with the immune system, which is critical in overcoming the immune evasion seen in PDAC. This evidence concerns the gene PDCD1 and neoplasm.